

## Embryonic Production of Nitric Oxide and Its Role in Implantation: A Pilot Study

C. Battaglia,<sup>1,4</sup> P. Ciotti,<sup>2</sup> L. Notarangelo,<sup>2</sup> R. Fratto,<sup>2</sup> F. Facchinetti,<sup>3</sup> and D. de Aloysio<sup>1</sup>

Submitted September 18, 2003; accepted October 1, 2003

**Purpose:** To investigate the ability of human embryos to produce nitric oxide (NO) and correlate its production with embryo quality and pregnancy rate.

**Methods:** Twenty-three women participated in the study and were submitted to controlled ovarian stimulation and intracytoplasmic sperm injection. Embryos were singularly cultured in medium microdrops of 50  $\mu\text{L}$  and were replaced, by transcervical transfer, at the 2- to 6-cell stage. In the culture media of each embryo the NO production was assessed by monitoring the levels of its stable oxidation products (nitrites/nitrates).

**Results:** All the 23 patients underwent embryo transfer. After microinjection 64 embryos were obtained. The mean number of transferred embryos was  $2.61 \pm 0.46$  and the pregnancy rate was 26%. The mean nitrite/nitrate concentrations of culture medium of each embryo was significantly higher ( $5.88 \pm 2.34 \mu\text{mol/L}$ ) than in pure P-1 medium ( $0.81 \pm 0.21 \mu\text{mol/L}$ ;  $p < 0.001$ ) demonstrating an embryonic secretion of NO. Comparing pregnant ( $7.34 \pm 2.72 \mu\text{mol/L}$ ) versus nonpregnant patients ( $5.53 \pm 1.49 \mu\text{mol/L}$ ;  $p = 0.022$ ), the mean nitrite/nitrate concentrations were significantly higher. Furthermore, the best quality embryos of pregnant women produced significantly higher nitrite/nitrate concentrations than those of not pregnant patients.

**Conclusions:** It seems that NO production in nidating embryos is increased and that it may be primarily associated with a better morphology and a better growth potential of developing embryos.

**KEY WORDS:** Embryo; ICSI; implantation; infertility; nitric oxide.

### INTRODUCTION

Helping infertile couples to have healthy children is one of the primary tasks of assisted reproductive technologies. To fulfil this task, reproductive medicine constantly needs to obtain information on physiology and pathophysiology of reproduction.

In the last years, nitric oxide (NO) has assumed an important functional role in the physiology of several organs and systems (1). Nitric oxide is a labile and difusible molecule that forms stable oxidized metabolites (nitrite/nitrate;  $\text{NO}_2^-/\text{NO}_3^-$ ) detectable in many biological fluids. In vivo, NO is formed from L-arginine either by a constitutive calcium-dependent, or a proinflammatory cytokine-inducible, NO-synthase (NOS) (2). Although the precise role of NO has not been elucidated, it has been suggested that NO induces vasodilation, inhibits platelet aggregation and smooth muscle cells proliferation, acts as a neurotransmitter in the neural system and as a cytotoxic agent for the invading microbes (2,3). Apart from the above functions, NO may be directly involved in the physiology of reproductive organs. The NO participates in

<sup>1</sup>III Department of Obstetrics and Gynecology, Alma Mater Studiorum – University of Bologna, Via Massarenti, 13, 40138 Bologna, Italy.

<sup>2</sup>Reproductive Medicine Unit, Alma Mater Studiorum – University of Bologna, Via Massarenti, 13, 40138 Bologna, Italy.

<sup>3</sup>Department of Obstetrics and Gynecology, University of Modena, Italy.

<sup>4</sup>To whom correspondence should be addressed; e-mail: battaglia@med.unibo.it.

perioovulatory modulation of ovarian blood flow (4–6) and seems to be involved in follicular maturation and ovulation (1,7). However, although the NO local synthesis within the uterus may be important for regulating endometrial, cervical, and myometrial activity (8), its role in embryonic implantation has not been fully explored.

Successful embryo implantation resembles an inflammatory reaction, with infiltration of leukocytes, vasodilation, and oedema (9) and it is strictly dependent on the synchrony between embryo development and the endometrial events that occur in the peri-implantation period of a fertile cycle (10). These local modifications are fundamental for the generation of the decidual tissue and involve the production of vasoactive agents such as prostaglandins, leukotrienes, platelet activating factor, and NO (11–14). A critical level of NO seems to be mandatory for the establishment of pregnancy. In fact, although Chwalisz *et al.* (15) demonstrated that NO is required for normal embryonic development, Barroso *et al.* (16) showed that high NO concentrations, in mice, may be cytotoxic and could alter either the embryo development in vitro and implantation in vivo.

The aim of this study was to investigate the ability of human embryos to produce NO and correlate the NO production with embryo quality and pregnancy rate.

## MATERIALS AND METHODS

The study protocol was approved by the institutional Ethics Review Committee. All the 23 women attending the Bologna University Infertility Clinic who participated in the study provided their informed consent.

The mean ( $\pm$ SD) age of the patients was  $35.2 \pm 4.2$  years (range 28–41), and the mean duration of infertility was  $6.8 \pm 3.2$  years (range 3–11). All patients were selected from women who suffered from tubal infertility. All had regular menstrual cycles ( $28 \pm 4$  days), and their partners were fertile according to World Health Organization's standards (17). Patients with concurrent illness were excluded from the study. Other exclusion criteria included body mass index [ $\text{BMI} = \text{weight (kg)}/\text{weight (m)}^2$ ]  $\geq 30$ , endometriosis, ovarian functional cyst, polycystic ovarian syndrome, unilateral ovarian resection, or ovariectomy. Likewise patients who were heavy smokers ( $>10$  cigarettes/day), and were hypertensive (systolic blood pressure  $>140$  mmHg and/or diastolic pressure  $>90$  mmHg) were ex-

cluded from the study. None of the women had received hormonal treatments for at least 4 months before the controlled ovarian hyperstimulation.

Controlled ovarian stimulation was achieved by an i.m. injection on day 20 of the cycle of GnRH agonist triptorelin (Decapeptyl 3.75; Ipsen, Milan, Italy) and, after pituitary desensitization (plasma estradiol concentration  $<100$  pmol/L; ovaries with no follicles  $>5$  mm in diameter and endometrial thickness  $<5$  mm), i.m. administration of pFSH (Metrodin HP; Serono, Rome, Italy; 225 IU in the first 3 days of the cycle, then in an individually assessed dosage).

When at least two follicles  $\geq 17$  mm in diameter were present, pFSH was withdrawn and 10,000 IU hCG (Profasi; Serono) were administered i.m. On the same day: (a) peripheral blood was obtained and plasma estradiol concentrations were determined by radioimmunoassay (RIA; Radim, Pomezia, Italy); and (b) ultrasonographic assessment of endometrial thickness was performed using a 6.0-MHz transvaginal transducer (Versa Plus; Siemens, Milan, Italy).

Ultrasonographic oocyte recovery was performed transvaginally 35–36 h after hCG injection. The retrieved oocytes were classified as mature, immature, or atretic on the basis of the morphology and appearance of the oocyte cumulus–corona complex according to published criteria (18). To obtain standardized condition, up to four mature oocytes/patient were selected and submitted to intracytoplasmic sperm injection (ICSI). The oocytes selected for insemination were singularly placed, under oil (Mineral Oil; Medi Cult, Mollehaven, Denmark), in medium microdrops of 50  $\mu\text{L}$  (IVF medium; Irvine Scientific, Santa Ana, CA) and incubated at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  atmosphere. After at least 3 h the eggs were briefly exposed to 40 IU/mL hyaluronidase (Medi Cult, Mollehaven, Denmark) and mechanically denuded (170–140–130  $\mu\text{m}$  denuding pipette; Cook, Melbourne, Australia). The denuded oocytes were examined under an inverted microscope to accurately evaluate the presence of the first polar body (1st PB) and maintained in culture until microinjection.

After 2–3 days of sexual abstinence, semen samples were produced by masturbation, collected in sterile specimen cups and allowed to liquefy at room temperature. Semen volume, pH, sperm concentration, motility, and morphology were determined following the WHO guidelines for semen analysis (17). All semen samples were washed in Flushing medium (Medi Cult, Mollehaven, Denmark) by centrifugation at  $200 \times g$  for 10 min and treated utilizing a discontinuous gradient technique (Pure Sperm; Medi Cult, Mollehaven, Denmark).

Intracytoplasmic sperm injection was performed as described by Van Steirteghem *et al.* (19).

To avoid ethical, legal, and religious problems, the supernumerary oocytes were cryopreserved as previously described (20).

The fertilization check (presence of two pronuclei and of the 2nd PB) was performed 16–18 h after sperm injection. Zygotes and embryos were singularly cultured in medium microdrops of 50  $\mu$ L (P-1 medium; Irvine Scientific, Santa Ana, CA) under oil.

To study the impact of embryo quality on NO production, the embryos were graded morphologically before replacement. The embryos were scored as follows: grade A, equal-sized blastomeres, no fragmentation; grade B, equal- or unequal-sized blastomeres, <20% fragmentation; grade C, equal- or unequal-sized blastomeres, 20–50% fragmentation; grade D, equal- or unequal-sized blastomeres, >50% fragmentation. Embryo transfer (ET) was performed 48 h after oocyte retrieval. Between one and four embryos were replaced at the 2- to 6-cell stage. Transcervical transfer was carried out using a Frydman catheter (SCS International; Genoa, Italy).

Vaginal progesterone (Esolut; Angelini, Rome, Italy) was prescribed as luteal phase support until the  $\beta$ -hCG assay was performed. A clinical pregnancy was diagnosed by ultrasonographic evidence of embryonic heart activity.

Immediately after ET, the culture medium of each embryo was collected in Eppendorf cryotubes (SGA/Diasint, Florence, Italy) and stored at  $-20^{\circ}\text{C}$  until  $\text{NO}^{-}$  was assayed.

Nitric oxide production was assessed by monitoring the culture media levels of stable oxidation products of NO metabolism ( $\text{NO}_2^{-}/\text{NO}_3^{-}$ ). Since very little or no  $\text{NO}_2^{-}$  is normally found in the biological fluids, no attempt was made to differentiate between  $\text{NO}_2^{-}$  and  $\text{NO}_3^{-}$  amounts; hence, results were reported as  $\text{NO}_2^{-}/\text{NO}_3^{-}$ . Nitrites/nitrates were assayed using the Greiss reaction with previously described procedures (21,22). All samples were analyzed in duplicate. The  $\text{NO}_2^{-}/\text{NO}_3^{-}$  concentration in the P-1 medium (Irvine Scientific) of five different bottles were assayed in duplicate. The  $\text{NO}_2^{-}/\text{NO}_3^{-}$  intra- and interassay coefficient of variation were 5.6 and 6.8% respectively.

### Statistical Analysis

A statistical analysis (SPSS software; SPSS Inc., Illinois, USA) was performed using the one-way analysis of variance with Bonferroni correction. The relationship between the parameters analyzed was as-


essed using the stepwise linear regression method. A probability of  $<0.05$  was considered statistically significant. Data are presented as mean  $\pm$  SD, unless otherwise indicated.

### RESULTS

All the 23 patients underwent ET and completed the study. No cycle was cancelled either because a “poor response” (estradiol plasma levels  $<1100$  pmol/L and/or  $<3$  follicles recruited by cycle day 8) or because a risk of hyperstimulation syndrome ( $>15$  follicles/ovary and/or estradiol plasma levels  $>9000$  pmol/L).

During the controlled ovarian hyperstimulation, the mean number of pFSH ampoules we used was  $45.4 \pm 10.3$  and the mean duration of pFSH treatment was  $12.5 \pm 2.1$  days. On the day of hCG administration, the number of recruited follicles was  $11.5 \pm 3.3$ ; the mean endometrial thickness was  $10.4 \pm 1.4$  mm; and the mean estradiol plasma level concentrations was  $7245 \pm 1105$  pmol/L. During ovum pick-up were collected 99 oocytes and among them 67 mature oocytes were submitted to ICSI. The remaining 33 oocytes were cryopreserved. After microinjection 64 embryos (fertilization rate = 95%) were obtained and their morphology allowed us to distinguish 16 (25%) grade A, 32 (50%) grade B, and 16 (25%) grade C + D embryos. The mean number of transferred embryos was  $2.61 \pm 0.46$  and the pregnancy rate was 26% (6/23). The pregnancy rate per cycle, per patient, and per ET were coincident since all the patients underwent to ET. Five single and one twin (implantation rate = 10.9%) pregnancies were obtained and all resulted in normal live births.

The mean  $\text{NO}_2^{-}/\text{NO}_3^{-}$  concentrations of culture medium of each embryo was significantly higher ( $5.88 \pm 2.34$   $\mu\text{mol/L}$ ; range 2.59–14.32  $\mu\text{mol/L}$ ; 10th percentile = 4.02  $\mu\text{mol/L}$ , 90th percentile = 8.49  $\mu\text{mol/L}$ ) than in pure P-1 medium ( $0.81 \pm 0.21$   $\mu\text{mol/L}$ ;  $p \leq 0.001$ ) demonstrating an embryonic secretion of  $\text{NO}_2^{-}/\text{NO}_3^{-}$ . No significant differences were observed between the  $\text{NO}_2^{-}/\text{NO}_3^{-}$  secretion of grade A ( $5.66 \pm 1.76$   $\mu\text{mol/L}$ ), grade B ( $6.14 \pm 2.15$   $\mu\text{mol/L}$ ), and grade C + D ( $5.86 \pm 2.71$   $\mu\text{mol/L}$ ) embryos. However, comparing pregnant versus nonpregnant patients, the mean  $\text{NO}_2^{-}/\text{NO}_3^{-}$  concentrations of culture medium of each embryo was significantly higher ( $7.34 \pm 2.72$   $\mu\text{mol/L}$ ) in the first than in the second group ( $5.53 \pm 1.49$   $\mu\text{mol/L}$ ;  $p = 0.022$ ). In addition, the best quality (grade A + B) embryos of pregnant women produced significant higher  $\text{NO}_2^{-}/\text{NO}_3^{-}$  concentrations



**Fig. 1.** The best quality (grade A + B) embryos of pregnant women produced significant higher  $\text{NO}_2^-/\text{NO}_3^-$  concentrations than those of not pregnant patients. No differences among the two groups were observed between grade C+D embryos.

than those of not pregnant (Fig. 1) patients. No differences among the two groups were observed between grade C + D embryos (Fig. 1). Furthermore, in seven cases, among the embryos belonging to the pregnant group, the  $\text{NO}_2^-/\text{NO}_3^-$  concentrations were above the 90th percentile and the transferred embryos were at the 6-cell stage. The endometrial thickness was not significantly different in pregnant and non-pregnant women.

No significant correlations were found between  $\text{NO}_2^-/\text{NO}_3^-$  concentrations, embryo grading, pregnancy rate, and estradiol circulating levels.

## DISCUSSION

The embryonic nidation is a critical process when pregnancy occurs. Successful implantation of blastocyst is, in fact, due to the synchrony between the embryo development and the endometrial transformation into the decidua (an intense vascularized tissue that encapsulates the developing embryo). The factors responsible of the endometrial/decidual cell transformation are still poorly understood and seem to involve vasoactive agents such as prostaglandins, leukotrienes, platelet activating factor, and NO (11–14).

The role of NO in the nidation process has been fundamentally studied in the rodent model and an increased expression of NO synthase has been found at the implantation site on the first days of pregnancy

(23). Furthermore, the administration of a  $N\omega$ -nitro-L-arginine methyl ester, a NOS inhibitor, reduces the number of successfully implanted embryos and indicates that the generation of NO is a primary step for embryonic implantation (24–26). In addition, Gouge *et al.* (27) recently showed that NO is required for the normal embryonic mitotic division and that the inhibition of NO, by altering the cyclic nucleotide production, has detrimental effects on embryonic development. On the other hand, Barroso *et al.* (16) demonstrated that, in mice, elevated NO concentrations, inhibit both embryo development in vitro and implantation in vivo. The NO-induced cytostasis and cytotoxicity may be due to a specific inhibition of mitochondrial respiration and DNA synthesis.

From the above data in rodents it is evident that the successful establishment of pregnancy requires a critical level of NO at the nidation site and that increased NO levels may be deleterious to implantation. In humans there are scant data on the specific role of NO in embryo development, decidual transformation, and embryo implantation. However, indirect evidences confirm that, depending on its concentrations, NO can both inhibit or stimulate embryonic development and implantation (28,29).

In this study we demonstrated, for the first time in humans at the best of our knowledge, an embryonic secretion of nitrites/nitrates. Although the NO production did not result correlated with embryo grading, the mean nitrite/nitrate concentrations of culture medium was significantly higher in the best quality embryos of pregnant than nonpregnant women. We speculated that the embryonic morphology is an expression of its growth potential and that the loss of any correlation between embryo grading and NO production may only be due to the low number of studied embryos.

It is well-known that each embryo has its own developmental potential, and that few cleaved embryos are competent to implant after IVF and develop throughout gestation. Our data showed that, in seven cases belonging to the pregnant group, the NO concentrations were above the 90th percentile and the embryos were at the 6-cell stage. The results we derived from this pilot study, led us to speculate that NO production in nidating embryos is increased and that it may be primarily associated with a better morphology and a better growth potential of developing embryos.

The above results were further associated with no significant differences in circulating estradiol levels and endometrial thickness demonstrating the limited value of these parameters in the blastocyst implant.

Although it is reported that elevated NO concentrations have been found in pathologic cases in which implantation failures occur (endometriosis, recurrent miscarriages, etc.) (30,31), we think that, if comprised in a physiological range, increased NO may act at different sites to promote implantation. It could contribute to embryonic implantation by increasing: endometrial vascular permeability; prostaglandin mediated decidualization; programmed cell death; extracellular matrix degradation; and uterine relaxation (2,3,32,33).

Although further larger prospective studies are necessary to elucidate the complex factors that control the reciprocal signalling relationship between maternal and embryonic tissues, it may be concluded that NO is actively produced by the developing embryos and may be deeply involved in embryo nidation.

## ACKNOWLEDGMENTS

The authors thank Dr Eleonora Porcu, Prof Stefano Venturoli, and the staff of Bologna University Infertility Clinic for their invaluable help and cooperation. They also thank Daniele Radi for expert assistance in laboratory assays.

## REFERENCES

- Anteby EY, Hurwitz A, Korach O, Revel A, Simon A, Finci-Yeheskel Z, Mayer M, Laufer N: Human follicular nitric oxide pathway: Relationship to follicular size, oestradiol concentrations and ovarian blood flow. *Hum Reprod* 1996;11:1947–1951
- Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. *Pharmacol Rev* 1991;43:109–142
- Rosselli M: Nitric oxide and reproduction. *Mol Hum Reprod* 1997;3:639–641
- Ben-Shlomo I, Adashi EY, Payne DW: The morphogenic/cytotoxic and prostaglandin stimulating activities of interleukin-1b in the rat ovary are NO independent. *J Clin Invest* 1994;94:1463–1469
- Battaglia C, Salvatori M, Maxia N, Petraglia F, Facchinetti F, Volpe A: Adjuvant L-arginine treatment for in vitro fertilization in poor responders patients. *Hum Reprod* 1999;14:1690–1697
- Battaglia C, Regnani C, Marsella T, Facchinetti F, Volpe A, Venturoli S, Flamigni C: Adjuvant L-arginine treatment in controlled ovarian hyperstimulation: A double-blind, randomized study. *Hum Reprod* 2002;3:659–665
- Tao YP, Misko TP, Howlett AC, Klein C: Nitric oxide, an endogenous regulator of Dictyostelium discoideum differentiation. *Development* 1997;124(18):3587–3595
- Telfer J, Lyall F, Norman JE, Cameron IT: Identification of nitric oxide synthase in human uterus. *Hum Reprod* 1995;10:19–23
- Weitlauf HM: Biology of Implantation. *In* The Physiology of Reproduction, E Knobil, JD Neill (eds), New York, Raven Press, 1994, pp 391–440
- Beier HM, Hegele-Hartung C, Mootz U, Beier-Hellwig K: Modification of endometrial cell biology using progesterone antagonists to manipulate the implantation window. *Hum Reprod* 1994;9(Suppl 1):98–115
- Kennedy TG, Lukash LA: Induction of decidualization in rats by the intrauterine infusion of prostaglandins. *Biol Reprod* 1982;27:253–260
- Yee G, Squires P, Cejic SS, Kennedy TG: Lipid mediators of implantation and decidualization. *J Lipid Mediat* 1993;6:525–534
- Acker G, Hecquet F, Etienne A, Braquet P, Mencia-Huerta JM: Role of Platelet-Activating Factor (PAF) in the ovoidimplantation in the rat: Effect of the specific PAF-acether antagonist, BN 52021. *Prostaglandins* 1988;35:233–241
- Novaro V, González E, Jawerbaum A, Rettori V, Canteros G, Gimeno F: Nitric oxide synthase regulation during embryonic implantation. *Reprod Fertil Dev* 1997;9:557–564
- Chwalisz K, Winterhager E, Thienel T, Garfield RE: Synergistic role of nitric oxide and progesterone during the establishment of pregnancy in the rat. *Hum Reprod* 1999;14:542–552
- Barroso R, Osuamkpe C, Nagamani M, Yallampalli C: Nitric oxide inhibits development of embryos and implantation in mice. *Mol Hum Reprod* 1999;4:503–507
- WHO: Laboratory Manual for the Examination of Human Semen and Semen Cervical Mucus Interaction. Cambridge, Cambridge University Press, 1992
- Acosta AA, Jones GS, Garcia JE, Sandow B, Veeck L, Mantzavinos T: Correlation of human menopausal gonadotropin/human chorionic gonadotropin stimulation and oocyte quality in an in vitro fertilization program. *Fertil Steril* 1984;41:196–201
- Van Steirteghem AC, Nagy Z, Joris H, Liu J, Staessen, C, Smits J, Wisanto A, Devroey P: High fertilization and implantation rates after intracytoplasmic sperm injection. *Hum Reprod* 1993;8:1061–1066
- Fabbri R, Porcu E, Marsella T, Rocchetta G, Venturoli S, Flamigni C: Human oocyte cryopreservation: New perspectives regarding oocyte survival. *Hum Reprod* 2001;16:411–416
- Clancy RM, Abramson SB: Novel synthesis of S-nitrosoglutathione and degradation by human neutrophils. *Ann Biochem* 1992;204:365–371
- Facchinetti F, De Martis S, Neri I, Caputo A, Volpe A: Effects of transdermal glyceryltrinitrate on 24-h blood pressure changes in patients with gestational hypertension. *Prenat Neonat Med* 1997;2:22–28
- Khorram O: Nitric oxide and its role in blastocyst implantation. *Rev Endocr Metab Disord* 2002;3:145–149
- Novaro V, Rettori V, Gonzalez ET: Interaction between uterine PGE and PGF<sub>2α</sub> production and the nitridergic system during embryonic implantation in the rat. *Prostaglandins* 1996;51:363–376
- Biswas S, Kabir SN, Pal AK: The role of nitric oxide in the process of implantation in rats. *J Reprod Fertil* 1998;114:157–161
- Ota H, Igarashi S, Oyama N, Suzuki Y, Tanaka T: Optimal levels of nitric oxide are crucial for implantation in mice. *Reprod Fertil Dev* 1999;11:183–188

27. Gouge RC, Marshburn P, Gordon BE, Nunley W, Huet-Hudson YM: Nitric oxide as a regulator of embryonic development. *Biol Reprod* 1998;58:875–879
28. Ariel I, Hochberg A, Shochina M: Endothelial nitric oxide synthase immunoreactivity in early gestation and in trophoblastic disease. *J Clin Pathol* 1998;51:427–431
29. Fabregues F, Balasch J, Manau D, Creus M, Jimenez W, Carmona FC, Vanrell JA: Circulating levels of nitric oxide in successful and unsuccessful implantation after *in vitro* fertilization and embryo transfer. Relationship to estradiol and progesterone. *Acta Obstet Gynecol Scand* 2000;79:564–569
30. Khorram O, Lessey BA: Altered expression of endothelial nitric oxide synthase (eNOS) in women with endometriosis. *Fertil Steril* 2000;74:521
31. Wilson R, McInnes I, Leung B, McKillop JH, Walker JJ: Altered interleukin 12 and nitric oxide levels in recurrent miscarriage. *Eur. J. Obstet Gynecol Reprod Biol* 1997;75:211–214
32. Novaro V, Pustovrh C, Colman-Lerner A, Radisky D, Lo Nostro F, Paz D, Jawerbaum A, González E: Nitric oxide induces gelatinase A (matrix metalloproteinase 2) during rat embryo implantation. *Fertil Steril* 2002;78:1278–1287
33. Buhimschi I, Ali M, Jain V, Chwalise K, Garfield RE: Differential regulation of nitric oxide in the rat uterus and cervix during pregnancy and labour. *Hum Reprod* 1996;11:1755–1766